Microbiota-derived genotoxin tilimycin generates colonic stem cell mutations.

CP: Microbiology antibiotics bacterial metabolite colorectal epithelium genotoxin gut microbiota intestinal stem cell necrotizing enterocolitis somatic mutation frequency

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
28 03 2023
Historique:
received: 28 04 2022
revised: 19 12 2022
accepted: 14 02 2023
medline: 3 4 2023
pubmed: 5 3 2023
entrez: 4 3 2023
Statut: ppublish

Résumé

The DNA-alkylating metabolite tilimycin is a microbial genotoxin. Intestinal accumulation of tilimycin in individuals carrying til+ Klebsiella spp. causes apoptotic erosion of the epithelium and colitis. Renewal of the intestinal lining and response to injury requires the activities of stem cells located at the base of intestinal crypts. This study interrogates the consequences of tilimycin-induced DNA damage to cycling stem cells. We charted the spatial distribution and luminal quantities of til metabolites in Klebsiella-colonized mice in the context of a complex microbial community. Loss of marker gene G6pd function indicates genetic aberrations in colorectal stem cells that became stabilized in monoclonal mutant crypts. Mice colonized with tilimycin-producing Klebsiella displayed both higher frequencies of somatic mutation and more mutations per affected individual than animals carrying a non-producing mutant. Our findings imply that genotoxic til+ Klebsiella may drive somatic genetic change in the colon and increase disease susceptibility in human hosts.

Identifiants

pubmed: 36870054
pii: S2211-1247(23)00210-3
doi: 10.1016/j.celrep.2023.112199
pii:
doi:

Substances chimiques

tilimycin 0
Mutagens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112199

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Lisa Pöltl (L)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.

Maksym Kitsera (M)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.

Sandra Raffl (S)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.

Stefan Schild (S)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria; BioTechMed-Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria.

Amar Cosic (A)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.

Sabine Kienesberger (S)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria; BioTechMed-Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria.

Katrin Unterhauser (K)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.

Georg Raber (G)

Institute of Chemistry, University of Graz, 8010 Graz, Austria.

Christian Lembacher-Fadum (C)

Institute of Organic Chemistry, Graz University of Technology, 8010 Graz, Austria.

Rolf Breinbauer (R)

BioTechMed-Graz, 8010 Graz, Austria; Institute of Organic Chemistry, Graz University of Technology, 8010 Graz, Austria.

Gregor Gorkiewicz (G)

BioTechMed-Graz, 8010 Graz, Austria; Diagnostic and Research Institute of Pathology, Medical University of Graz, 8036 Graz, Austria.

Carlos Sebastian (C)

Candiolo Cancer Institute-FPO, IRCCS, 10060 Candiolo, Italy; Departament de Biologia Cellular, Fisiologia i Immunologia, Facultad de Biologia, Universitat de Barcelona (UB), 08028 Barcelona, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), 08028 Barcelona, Spain.

Gerald Hoefler (G)

Diagnostic and Research Institute of Pathology, Medical University of Graz, 8036 Graz, Austria.

Ellen L Zechner (EL)

Institute of Molecular Biosciences, University of Graz, 8010 Graz, Austria; BioTechMed-Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria. Electronic address: ellen.zechner@uni-graz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH